Rocket Pharmaceuticals Ownership
| RCKT Stock | USD 8.43 0.11 1.32% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 94 M | Current Value 95 M | Avarage Shares Outstanding 46.5 M | Quarterly Volatility 30.7 M |
Rocket |
Rocket Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.94. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rocket Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 2.73. The firm last dividend was issued on the 5th of January 2018. Rocket Pharmaceuticals had 1:4 split on the 5th of January 2018. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. Rocket Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people. To find out more about Rocket Pharmaceuticals contact Gaurav MD at 609 659 8001 or learn more at https://www.rocketpharma.com.Besides selling stocks to institutional investors, Rocket Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Rocket Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Rocket Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Rocket Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Rocket Pharmaceuticals Insider Trades History
Roughly 3.0% of Rocket Pharmaceuticals are currently held by insiders. Unlike Rocket Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Rocket Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Rocket Pharmaceuticals' insider trades
Rocket Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rocket Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rocket Pharmaceuticals backward and forwards among themselves. Rocket Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rocket Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.6 M | Boxer Capital Management, Llc | 2024-12-31 | 1.5 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.3 M | Venbio Select Advisor Llc | 2024-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.2 M | Cowen And Company, Llc | 2024-09-30 | 1.1 M | The Toronto-dominion Bank | 2024-12-31 | 1.1 M | Rtw Investments, Llc | 2024-12-31 | 17.7 M | Wellington Management Company Llp | 2024-12-31 | 14 M |
Rocket Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rocket Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rocket Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rocket Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rocket Pharmaceuticals Outstanding Bonds
Rocket Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rocket Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rocket bonds can be classified according to their maturity, which is the date when Rocket Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US77314EAA64 Corp BondUS77314EAA64 | View | |
| US77310VAA26 Corp BondUS77310VAA26 | View | |
| US77313LAA17 Corp BondUS77313LAA17 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| US77313LAB99 Corp BondUS77313LAB99 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Rocket Pharmaceuticals Corporate Filings
| 3rd of March 2025 Other Reports | ViewVerify | |
F4 | 27th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify | |
F3 | 5th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.